BRIEF published on 10/10/2025 at 18:35, 8 months 16 days ago Publication mensuelle des droits de vote de Theraclion Investissement Droits De Vote Capital Social Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 8 months 16 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
PRESS RELEASE published on 10/10/2025 at 18:30, 8 months 16 days ago Informations privilégiées / Autres communiqués Communiqué mensuel sur les droits de vote et actions de Theraclion, société française de MedTech. Détails des actions en circulation et droits de vote réels Euronext PEA PME MedTech France Theraclion
BRIEF published on 09/15/2025 at 18:35, 9 months 11 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
BRIEF published on 09/15/2025 at 18:35, 9 months 11 days ago Theraclion Réussit son Étude Pivotal avec un Taux d'Occlusion de 96,8 % FDA Essai Clinique Theraclion SONOVEIN® Varices
PRESS RELEASE published on 09/15/2025 at 18:30, 9 months 11 days ago Informations privilégiées / Autres communiqués Theraclion annonce le succès de son étude pivotale américaine FDA avec un taux d'occlusion de 96,8% pour Sonovein®, sa plateforme de traitement des varices par ultrasons focalisés de haute intensité FDA Theraclion SONOVEIN Étude Pivotale Occlusion
PRESS RELEASE published on 09/15/2025 at 18:30, 9 months 11 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
BRIEF published on 07/25/2025 at 18:35, 11 months 1 day ago Theraclion in full expansion in the first half of 2025 Financial Results Clinical Trials Business Expansion Theraclion SONOVEIN
BRIEF published on 07/25/2025 at 18:35, 11 months 1 day ago Theraclion en pleine expansion au premier semestre 2025 Résultats Financiers Essais Cliniques Expansion Commerciale Theraclion SONOVEIN
PRESS RELEASE published on 07/25/2025 at 18:30, 11 months 1 day ago Inside Information / News release on accounts, results Theraclion reports strong growth in S1 2025 with increased revenue and expansion into new markets. Key achievements include 30% rise in consumables sales and completion of pivotal FDA clinical trial follow-up period Revenue Growth Business Expansion Theraclion FDA Clinical Trial S1 2025
Published on 06/27/2026 at 00:00, 52 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 hour 52 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 2 hours 2 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 2 hours 37 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 47 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 48 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 hour 16 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 hour 16 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 hour 24 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
